263. Cerebrotendinous xanthomatosis
5 clinical trials,   10 drugs   (DrugBank: 2 drugs),   2 drug target genes,   4 drug target pathways

Searched query = "Cerebrotendinous xanthomatosis", "27-hydroxylase deficiency", "CYP27 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-205157
03/8/202013/02/2020An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3)An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3) Cerebrotendinous xanthomatosisIntervention name : FPF1011
INN of the intervention : Chenodeoxycholic acid
Dosage And administration of the intervention : Dose of chenodeoxycholic acid is 750 mg/day for patients aged 20 or older, and 15 mg/kg/day under ages 20, administered orally in three divided doses a day.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Fujimoto Pharmaceutical CorporationNULLrecruiting0BOTH5Phase 3Japan
2NCT04270682
(ClinicalTrials.gov)
January 31, 202012/2/2020Study to Evaluate Patients With Cerebrotendinous XanthomatosisA Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous XanthomatosisCTXDrug: Blinded CDCA 250 mg TID;Drug: Placebo;Drug: Open-Label CDCA 250 mg TID;Drug: Rescue Medication CDCA 250 mg TID;Drug: CDCA Weight-Based Dose TIDTravere Therapeutics, Inc.NULLRecruiting1 MonthN/AAll12Phase 3United States
3NCT01613898
(ClinicalTrials.gov)
August 201022/5/2012Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous XanthomatosisEvaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous XanthomatosisCerebrotendinous Xanthomatosis (CTX)Biological: Blood testsSheba Medical CenterNULLRecruiting10 YearsN/ABoth17N/AIsrael
4NCT00018694
(ClinicalTrials.gov)
October 19993/7/2001Cholestanol in HumansBiologic Significance of Cholestanol in ManCerebrotendinous XanthomatosisDrug: Chenodeoxycholic AcidDepartment of Veterans AffairsNULLWithdrawn5 Years80 YearsBoth0N/AUnited States
5NCT00004346
(ClinicalTrials.gov)
January 199618/10/1999Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous XanthomatosisEffects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous XanthomatosisDrug: chenodeoxycholic acid;Drug: lovastatinNational Center for Research Resources (NCRR)Oregon Health and Science UniversityRecruitingN/AN/ABoth5Phase 2United States